2023
Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders
Ngwube A, Shah N, Schulz G, Krishnamurti L, Shenoy S. Abatacept-Prophylaxis Based Haploidentical Transplantation May Allow Sustained Engraftment and Offset Gvhd in Non-Malignant Disorders. Blood 2023, 142: 4901. DOI: 10.1182/blood-2023-191145.Peer-Reviewed Original ResearchNon-malignant disordersPost-transplant cyclophosphamideSickle cell diseaseGVHD prophylaxisHematopoietic transplantationEvaluable patientsHaploidentical transplantationImmune suppressionBone marrowFirst year post-HCTGrade 1 acute GVHDChronic GVHD riskChronic skin GVHDGVHD-free survivalPost-transplant lymphoproliferationsRadiation-containing regimensYear post-HCTPhase 2 trialReduced intensity conditioningSerious infectious complicationsSystemic immune suppressionT-cell chimerismAllogeneic hematopoietic transplantationPrimary outcome measureStem cell boostSafety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
Garcia-Manero G, Ooi M, Lao Z, Gill H, Abaza Y, Stahl M, Haque T, DeZern A, Greenberg P, Pelletier M, Singh A, Carreon D, Beaulieu V, Woo J. Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study. Blood 2023, 142: 3250. DOI: 10.1182/blood-2023-174642.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaCMML-specific prognostic scoring systemErythropoiesis-stimulating agentsDose-expansion partPrognostic scoring systemMyelodysplastic syndromeHypomethylating agentsLR-MDSEastern Cooperative Oncology Group performance statusIntermediate risk myelodysplastic syndromePredictive markers of efficacyDose of study treatmentInternational Prognostic Scoring SystemIL-18Colony-stimulating growth factorScoring systemAllogeneic hematopoietic transplantationBone marrow aspirate/biopsyPhase 1b studyProgression-free survivalTime to progressionPotential curative optionRisk myelodysplastic syndromesDuration of responseBone marrow assessment
2010
Abrogation of Donor T Cell IL-21 Signaling Leads to Tissue-Specific Modulation of Immunity and Separation of Gvhd From GVL
Hanash A, Kappel L, Yim N, Nejat R, Goldberg G, Smith O, Rao U, Dykstra L, Na I, Holland A, Liu C, Murphy G, Leonard W, Heller G, van den Brink M. Abrogation of Donor T Cell IL-21 Signaling Leads to Tissue-Specific Modulation of Immunity and Separation of Gvhd From GVL. Blood 2010, 116: 729. DOI: 10.1182/blood.v116.21.729.729.Peer-Reviewed Original ResearchDonor T cellsSeparation of GVHDMesenteric lymph nodesKO T cellsCytokine-producing CD4 T cellsCD4 T cellsIL-21Lymph nodesT cellsTissue-specific modulationWild-type donor T cellsSmall intestineDonor CD8 T cellsT cell-mediated GVHDT cell cytokine productionPeripheral T cell functionBone marrow transplant modelOnly curative therapyAllogeneic hematopoietic transplantationCD8 T cellsPeripheral lymph nodesT cell responsesPro-inflammatory cytokinesCell cytokine productionIL-21 signalingStem cell therapeutics: potential in the treatment of inflammatory bowel disease
Swenson E, Theise N. Stem cell therapeutics: potential in the treatment of inflammatory bowel disease. Clinical And Experimental Gastroenterology 2010, 3: 1-10. DOI: 10.2147/ceg.s12187482.Peer-Reviewed Original ResearchInflammatory bowel diseaseAllogeneic hematopoietic transplantationHematopoietic stem cellsTreatment of inflammatory bowel diseaseHematopoietic transplantationPredisposition to inflammatory bowel diseaseHost immune responseMesenchymal stem cellsStem cellsGenetic predisposition to inflammatory bowel diseaseSystemically infused mesenchymal stem cellsFistulas associated with Crohn's diseaseGraft-versus-host diseaseImmune responseHematopoietic stem cell transplantationBowel diseaseAutologous hematopoietic transplantationGraft-versus-hostStem cell transplantationDownregulate host immune responsesRisk of complicationsStem cell therapyStem cell therapy applicationsAutologous hematopoietic reconstitutionBlood cell linesStem cell therapeutics: potential in the treatment of inflammatory bowel disease
Swenson E, Theise N. Stem cell therapeutics: potential in the treatment of inflammatory bowel disease. Clinical And Experimental Gastroenterology 2010, Volume 3: 1-10. PMID: 21694840, PMCID: PMC3108654, DOI: 10.2147/ceg.s6836.Peer-Reviewed Original ResearchInflammatory bowel diseaseAllogeneic hematopoietic transplantationHost immune responseHematopoietic transplantationMesenchymal stem cellsBlood cell linesBowel diseaseImmune responseGenetic predispositionStem cellsLarge clinical trialsAutologous hematopoietic transplantationAutologous hematopoietic reconstitutionHost diseaseCrohn's diseaseMucosal immunityClinical trialsHematopoietic reconstitutionSmall seriesTransplantationGreater riskCell therapyDiseaseDonor cellsBaseline state
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply